Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DarioHealthDRIO +1.15%56 3-Year EBITDA Growth Rate is 42.60% as of Jun. 2026, which is 1% above its 10-year median of 42.20. GuruFocus rates DRIO with a GF Score™ of 56/100 and a GF Value™ of $4.49 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 527 Healthcare Providers & Services companies, DarioHealth ranks better than 87.48% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 42.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 39.50% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 38.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of DarioHealth was 61.40% per year. The lowest was 28.00% per year. And the median was 42.20% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
DarioHealth 3-Year EBITDA Growth Rate Related Terms
DRIO vs ONMD, DH, VASO: 3-Year EBITDA Growth Rate Comparison
For the Health Information Services subindustry, DarioHealth's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DarioHealth 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, DarioHealth's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where DarioHealth's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 42.60% mean?
DarioHealth (DRIO) has a 3-Year EBITDA Growth Rate of 42.60% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for DarioHealth and its competitors. This is near median its historical median of 42.20. Over the past decade, DarioHealth's 3-Year EBITDA Growth Rate has ranged from 28.00 to 61.40. According to the industry distribution chart, DarioHealth ranks #66 out of 527 companies in the Healthcare Providers & Services industry, placing it in the top 12.5%.
Is DarioHealth's 3-Year EBITDA Growth Rate too high?
DarioHealth's current 3-Year EBITDA Growth Rate of 42.60% is near median its 10-year median of 42.20. Over the past 10 years, this metric has ranged from a low of 28.00 to a high of 61.40. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 10.20. DarioHealth's value of 42.60% is 317.6% above this industry median. Based on the distribution chart, DarioHealth ranks #66 out of 527 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, DarioHealth has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does DarioHealth's 3-Year EBITDA Growth Rate compare to ONMD and DH?
According to the Healthcare Providers & Services industry distribution chart, DarioHealth ranks #66 out of 527 companies for 3-Year EBITDA Growth Rate. This places DarioHealth in the top 13% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 10.20. DarioHealth's value of 42.60% is 317.6% above this benchmark. Historically, DarioHealth's own 3-Year EBITDA Growth Rate has ranged from 28.00 to 61.40 over the past decade. While the company's 10-year median is 42.20 vs. the industry median of 10.20, DarioHealth has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.20, based on 527 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DarioHealth's current 3-Year EBITDA Growth Rate of 42.60% is 317.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for DarioHealth and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DarioHealth's current 3-Year EBITDA Growth Rate is 42.60%, which is near median its own 10-year median of 42.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DarioHealth stock overvalued right now?
Based on GuruFocus' analysis, DarioHealth (DRIO) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.49, compared to a current price of $7.49 — trading 66.8% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 42.60%, which is near median its 10-year median of 42.20 and 317.6% above the Healthcare Providers & Services industry median of 10.20. DarioHealth's overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For DarioHealth (DRIO), the current 3-Year EBITDA Growth Rate is 42.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DarioHealth (DRIO) Overvalued in 2026?
Based on GuruFocus' analysis, DarioHealth stock appears to be overvalued.
The current stock price of $7.49 is trading 66.8% above its estimated GF Value™ of $4.49.
GuruFocus considers DarioHealth to be Significantly Overvalued.
Key valuation signals for DRIO:
3-Year EBITDA Growth Rate: 42.60% (near median its 10-year median of 42.20)
GF Value™: $4.49 vs. price of $7.49 (66.8% above fair value)
Industry Position: 317.6% above the Healthcare Providers & Services median (#66 of 527)
No single metric tells the full story. See the DRIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. The company vertically integrated a health intelligence platform with a mission to power the behavior changes that drive greater health. Unlike software-only digital health platforms, Dario owns the complete chain of value in chronic care management - connected FDA-cleared hardware devices that generate continuous physiological data, and AI built on that proprietary data. The company focuses on delivering user experiences, longer sustained engagement, and stronger clinical outcomes, at affordable prices, which then delivers the highest return on investment in the industry.
56GF Score
Get the complete analysis for DRIO
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DRIO has been successfully added to your 
